Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pulse Biosciences CS
(NQ:
PLSE
)
10.75
+0.78 (+7.82%)
Streaming Delayed Price
Updated: 10:30 AM EDT, Jun 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
34,689
Open
9.970
Bid (Size)
10.60 (4)
Ask (Size)
10.87 (4)
Prev. Close
9.970
Today's Range
9.910 - 10.75
52wk Range
3.780 - 14.96
Shares Outstanding
54,902,942
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
May 31, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
May 31, 2024
Via
Benzinga
Performance
YTD
-2.45%
-2.45%
1 Month
-19.29%
-19.29%
3 Month
+27.98%
+27.98%
6 Month
-16.28%
-16.28%
1 Year
+69.83%
+69.83%
More News
Read More
12 Health Care Stocks Moving In Friday's Pre-Market Session
May 31, 2024
Via
Benzinga
PLSE Stock Earnings: Pulse Biosciences Reported Results for Q1 2024
May 07, 2024
Via
InvestorPlace
PLSE Stock Earnings: Pulse Biosciences Reported Results for Q4 2023
March 28, 2024
Via
InvestorPlace
Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000
May 20, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences’ CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting
May 16, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Enhances Executive Leadership Team
May 14, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System
May 09, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
May 15, 2024
Via
Benzinga
Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results
May 07, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000
May 02, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024
April 24, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Why Nuvve Holding Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Monday's Mid-Day Session
April 01, 2024
Via
Benzinga
Oxford Industries, PVH And 3 Stocks To Watch Heading Into Monday
April 01, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
March 29, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
March 28, 2024
Via
Benzinga
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results
March 28, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Announces Plans to Initiate a Rights Offering
March 28, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Earnings Scheduled For March 28, 2024
March 28, 2024
Via
Benzinga
Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024
March 14, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 11, 2024
Via
Benzinga
Exposures
Product Safety
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System
March 08, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study
February 14, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium
January 31, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.